Drug Profile
Melanoma vaccine Magevac - Therion
Alternative Names: Magevac; Magevac melanoma vaccine; TBC Mage-1Latest Information Update: 06 Apr 2022
Price :
$50
*
At a glance
- Originator Therion Biologics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 11 Jul 2002 No development reported - Phase-II for Malignant melanoma in USA (unspecified route)
- 24 Dec 1999 Pasteur Mérieux Connaught is now a subsidiary of Aventis and its new name is Aventis Pasteur
- 20 Feb 1997 Phase-II clinical trials for Malignant melanoma in USA (Unknown route)